Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients

CURRENT STATUS: ACCEPTED

Preprint: Please note that this article has not completed peer review.

Cristina Roca-Oporto
Institute of Biomedicine of Seville/University Hospital Virgen del Rocío

Tania Cebrero-Cangueiro
Institute of Biomedicine of Seville

María Luisa Gil-Marqués
Institute of Biomedicine of Seville

Gema Labrador-Herrera
Institute of Biomedicine of Seville

Younes Smani
Institute of Biomedicine of Seville

Francisco M. González-Roncero
University Hospital Virgen del Rocío

Luis Miguel Marín-Gómez
University Hospital Virgen del Rocío

Jerónimo Pachón
Institute of Biomedicine of Seville, University of Seville

Maria Eugenia Pachón-Ibáñez
Institute of Biomedicine of Seville

✉ mpachon-ibis@us.es Corresponding Author
ORCiD: https://orcid.org/0000-0001-7969-8162

Elisa Cordero
Institute of Biomedicine of Seville, University Hospital Virgen del Rocío
SUBJECT AREAS
Infectious Diseases

KEYWORDS
Streptococcus pneumoniae, Solid Organ Transplant recipients and nasopharyngeal carriage
Abstract
Background: S. pneumoniae is the leading cause of community-acquired pneumonia in the solid organ transplant recipient (SOTR); nevertheless, the prevalence of colonization and of the colonizing/infecting serotypes has not been studied in this population. In this context, the aim of the present study was to describe the rate, characteristics, and clinical impact of S. pneumoniae nasopharyngeal carriage. Methods: A prospective observational cohort of Solid Organ Transplant recipients (SOTR) was held at the University Hospital Virgen del Rocío, Seville, Spain with the aim to evaluate the S. pneumoniae colonization and the serotype prevalence in SOTR. Two different pharyngeal swabs samples from 500 patients were included in two different seasonal periods winter and spring/summer. Optochin and bile solubility tests were performed for the isolation of the strains. Antimicrobial susceptibility studies (MICs, mg/l) of levofloxacin, trimethoprim-sulfamethoxazole, penicillin, amoxicillin, cefotaxime, ceftriaxone, erythromycin, azithromycin and vancomycin for each isolate were determined by E-test strips. Capsular typing was done by sequential multiplex PCR reactions. A multivariate logistic regression analysis of factors potentially associated with pneumococcal nasopharyngeal carriage and disease was performed. Results: Twenty-six (5.6%) and fifteen (3.2%) patients were colonized in winter and spring/summer periods, respectively. Colonized SOT recipients compared to non-colonized patients were more frequently men (79.5% vs. 63.1%, P<0.05) and cohabitated regularly with children (59% vs. 32.2%, P<0.001). The most prevalent serotype in both studied periods was 35B. Forty-five percent of total isolates were included in the pneumococcal vaccine PPV23. Trimethoprim-sulfamethoxazole and macrolides were the less active antibiotics. Three patients had non-bacteremic pneumococcal pneumonia, and two of them died. Conclusions: Pneumococcal colonization in SOTR is low with the most colonizing serotypes not included in the pneumococcal vaccines.

Background
Streptococcus pneumoniae is one of the major causes of death worldwide (1, 2). Invasive pneumococcal disease (IPD) is an important cause of disease in the elderly and young children (<1year), with an incidence rate of 13.8 and 11.3 cases per 100,000 population, respectively (1).
Other medical conditions such as transplantation also increase the risk of IPD (3-5).

In solid organ transplant (SOTR), *S. pneumoniae* can be a significant reason for morbidity and mortality, including non-invasive and invasive disease, with a 12.8-fold greater incidence of IPD compared to the general population (4). Specific incidences vary according to the organ transplanted, with an incidence in kidney, lung, and liver transplant recipients of 1.04, 2.39, and 3.54 per 1000 transplant recipients/year (4). Mortality, although not significant, has been higher in SOT recipients compared with non-immunosuppressed patients (28.6% vs. 14.1%) (4, 9).

Among the virulence factors of *S. pneumoniae*, polysaccharide capsule is one of the most important. Approximately ninety different pneumococcal serotypes have been identified depending on the chemical and antigenic differences of the capsule (10), twenty of which had been described as causing most IPDs (11, 12). The awareness of which serotypes are the most invasive has allowed the development of current vaccines (13). In SOTR, recommendations emphasize the importance of vaccinating all candidates before transplantation (14, 15); however, this goal is still far from reality (16, 17). A systematic review published by Eckerle et al. (18) in 2013 demonstrated that recommendations for the vaccination of SOTR are based on evidence from studies in healthy persons, with an urgent need to conduct vaccination trials in well-defined SOTR cohorts.

The colonization of the nasopharynx is an initial step for the evolution of IPD with transmission from human carriers (19). Again, pneumococcal colonization has been mostly studied in children (20-22). In healthy adults, the data about *S. pneumoniae* nasopharyngeal carriage is limited, with reported colonization rates of 4-13% (21, 23). Information addressing *S. pneumoniae* colonization in the immunosuppressed population is scarce. Despite the significance of IPD in the transplant setting, no studies address pneumococcal colonization in SOT recipients. This information would be very useful to help understand the dynamics of serotypes in this population and learn if these serotypes are included in the vaccines currently used. The information available on serotype distribution consists only of a series of cases of IPD (4, 6-8), and vaccine recommendations have been made extrapolating data from healthy children.

In this study, we describe the rate of *S. pneumoniae* colonization in SOTR in two different seasonal
periods, the capsular serotypes and the antimicrobial susceptibility/resistance pattern.

Methods

**Study design**

A prospective observational cohort of SOTR was held at the University Hospital Virgen del Rocío, Seville, Spain. All patients included met the following inclusion criteria: a) adult patients (≥16 years); b) SOT recipients conducting their monitoring visits at the study center during the period of inclusion; c) survival after the transplant longer than 7 days; and d) written informed consent. Patients were excluded if they did not attend regular outpatient follow-up. A sample of 500 patients was included, expecting 20% of nasopharyngeal pneumococcal carriage, as in other immunosuppressed patients (3, 23, 24).

All patients were attended to in the outpatients’ clinic twice: at winter (December 2014–February 2015) and six months thereafter, spring/summer (June–August 2015). In each of these dates, structured interviews, as well as microbiological studies, were carried out. Clinical data of each patient regarding demographics, household contacts, contact with pneumococcal vaccinated and unvaccinated children, previous pneumococcal and influenza vaccination, transplant-related variables such as organ type, time from the transplantation, immunosuppression regimens and prior rejection, as well as chronic co-morbidities, antibiotic use in the last three months, prior hospitalization in the previous 30 days, and respiratory symptoms were obtained.

In cases of pneumococcal disease, all needed extra visits were performed, and clinical signs and symptoms, biochemical analysis, chest X-ray findings, antiviral and antibacterial therapies, concomitant or secondary infections, and outcomes, including mortality, were recorded.

**Sampling and Isolation**

Two different combined nasopharyngeal swab samples were obtained from each patient in both winter and spring/summer visits to increase detection rate (25, 26). Samples were obtained by using a sterile transport swab (EO36-REV.00, COPAN, Brescia, Italy), and swabs were placed in a tube with 1.0 ml of AMIES transport medium according to the pneumococcal carriage studies protocol of the World Health Organization (25, 26). The samples were cultured on Columbia Blood agar in 5% CO₂ at
37°C, and the α-hemolytic colonies were tested for optochin susceptibility and bile solubility (27). Pneumococcal isolates were stored at -80°C in skimmed milk until further analysis.

**Antimicrobial susceptibility studies**

Minimum inhibitory concentrations (MICs, mg/l) of levofloxacin, trimethoprim-sulfamethoxazole, penicillin, amoxicillin, cefotaxime, ceftriaxone, erythromycin, azithromycin and vancomycin for each *S. pneumoniae* isolate were determined using E-test strips (28). MIC results were interpreted for all the antibiotics according to the Clinical & Laboratory Standards Institute CLSI, (29) breakpoint.

Studies were performed in duplicate.

**Capsular typing**

Isolates were typed using the modified scheme of sequential multiplex PCR protocol with sequential reactions described previously (30-32). The serotypes studied were: 1, 2, 3, 4, 5, 6A/B, 6C/D, 7C/B/40, 7F, 8, 9N/L, 9V/A, 10A, 11A/D, 12F/A, 14, 15A, 15B/C, 16F, 17F, 18C/A/B/F, 19A, 19F, 20, 22F/A, 23A, 23B, 23F, 31, 33F, 34, 35B, 35F/47F, 37 and 38/25F. Briefly, each of the reactions included four serotype-specific primer pairs and a conserved region of the cps operon as internal positive control.

**Statistical analysis**

Data obtained in the study was analysed using the SPSS statistical software (version 24.0, SPSS Inc, Chicago, Illinois). A descriptive analysis of all data was performed. The chi-square test was used for categorical variables and the t-Student for continuous variables, when appropriate. A multivariate logistic regression analysis of factors potentially associated with pneumococcal nasopharyngeal carriage and disease was performed, including significant variables in the bivariate analyses and clinically relevant variables. Statistical significance was established at *P*<0.05.

**Results**

**Characteristics of the Study Population**

Five hundred SOT recipients were included in the study: 353 (70.6%) were kidney recipients, 106 (21.2%) liver recipients and 39 (7.9%) heart recipients. Most patients received tacrolimus, mycophenolate and steroids as immunosuppressant therapy. Twenty-four percent of patients reported having received pneumococcal vaccination. Clinical and demographic data are shown in
In winter 500 samples were collected, while in spring/summer 461 samples were. The difference in samples collection was due to 39 patients (7.8%) not attending to the spring/summer visit.

**Pneumococcal Carriage and Infection**

Twenty-six patients (5.6%) were colonized in winter and 15 (3.2%) in spring/summer ($P=0.06$). During the study period, three female patients (age range 53-71) were diagnosed with non-bacteremic pneumococcal pneumonia (Table 2); two of whom died.

The overall pneumococcal colonization rate in the 961 samples obtained was 4%. There were two patients with pneumococcal colonization in both studied periods. Colonized SOT recipients compared to non-colonized patients were more frequently men (79.5% vs. 63.1%, $P<0.05$) and cohabitated regularly with children (59% vs. 32.2%, $P<0.001$). In multivariable analysis these factors were also related to pneumococcal carriage: sex (men) OR 0.44 (CI95% 0.20–0.98) and cohabiting with children OR 2.90 (CI95% 1.5–5.77) (Table 3). There was no relationship between pneumococcal carriage and the immunosuppressant agents used, type of transplant or time since the transplant, pointing out that the immunosuppression was not related to the colonization status (Table 1).

Six colonized patients (15.4%) and 115 non-colonized patients (24.9%) had received pneumococcal vaccine prior to their inclusion ($P<0.05$). At the end of the study follow-up, 10 patients (2%) died; 7 (1.4%) lost the graft and 2 (0.4%) suffered an organ rejection. Colonized and non-colonized SOT recipients had similar outcomes regarding the incidence of pneumococcal disease, rejection, as well as graft and patients’ survival (Table 1).

**Characteristics of Pneumococcal Isolates**

During the winter period, 26 different serotypes were identified. The most prevalent serotypes were (in decreasing order): 35B (38.5%), 19A and 23A (11.5%), 6A/6B, 4, 6C/D, 9N/L and 23B (7.7% each) (Fig. 1). Overall, 52.7% of the winter isolates were included PCV23, while 47.2% were not included. Moreover, in 8 of the winter patients (30.8%) with pneumococcal isolates, no serotypes were identified by the molecular method used.

Sixteen isolates were resistant to azithromycin and erythromycin (36.36%), 15 isolates to
clarithromycin (34.09%), 14 isolates to trimethoprim-sulfamethoxazole (31.82%), 2 isolates to oral penicillin (18.18%), and none to intravenous penicillin, amoxicillin, cefotaxime, ceftriaxone, levofloxacin and vancomycin (See Supplementary Table 1, Additional file 1).

In the spring/summer period, 15 different serotypes were identified, 35B (53.3%), 19A, 11A/D, and 38/25F (13.3%) (in decreasing order) being the most prevalent ones (Fig. 1). Moreover, 33.3% of the spring/summer isolates were included in PPV23, while 66.6% were not included. The serotype of a patient of the spring/summer period (6.7%) could not be identified with the molecular method used. A reduction in the rate of antimicrobial resistance was observed in this period. Six isolates were resistant to trimethoprim-sulfamethoxazole (27.27%), 4 isolates to oral penicillin, azithromycin, erythromycin and clarithromycin (18.18%), and 2 isolates to amoxicillin (9.09%), and as in the winter period no isolate was resistant to intravenous penicillin, cefotaxime, ceftriaxone, levofloxacin and vancomycin (See Supplementary Table 2, Additional file 2).

The multiple-serotype carriage was similar in both study periods: 53.8% and 46.6%, respectively. Two patients were colonized during both periods with the capsular serotype 19A, and one of them was also colonized with the capsular 35B serotype in both periods.

Taking into account all the pneumococcal isolates collected in the study (n=57), the most frequent capsular serotypes were 35B (31.6%), 19A (8.77%) and 23A (7.02%). Twenty-six (45.6%) serotypes were included in any of the pneumococcal vaccines (PCV13 and PPV23), while 31 (54.4%) serotypes were not included.

On the basis of CLSI breakpoints, the percentages of resistant isolates were 30.3% for trimethoprim-sulfamethoxazole, azithromycin and erythromycin, 28.79% for clarithromycin, 9.09% and 3.03% for oral penicillin and amoxicillin, respectively. No resistance was observed in the cases of intravenous penicillin, cefotaxime, ceftriaxone, levofloxacin, and vancomycin (Table 4).

Discussion
To our knowledge this is the first study conducted to evaluate pneumococcal colonization in SOT recipients. In this study we found that colonization incidence is lower than reported in other immunosuppressed patients such as HIV-infected adults (23, 24) and has no relation with the
seasonal period studied. Colonized SOTR were more frequently men who cohabited with children. Moreover, almost half of the serotypes found were not included in the vaccines.

In the present study, as reported for non-immunocompromised patients (33-36), the colonization rate was less than 5% of the SOT recipients. This rate is considerably lower than that observed in healthy children (up to 54%) (37, 38). Indeed, there was no relationship between pneumococcal carriage and the immunosuppressant agents used, type of transplant or time since transplantation, pointing out that the immunosuppression was not related to the colonization status.

A seasonal effect trend on the rate of pneumococcal colonization in SOTR was observed. In accordance with it, Numminen et al. (39), in a cohort of 223 infants in Asia, in 2015, concluded that climate did affect seasonal pneumococcal transmission, which acted similarly across the studied geographical regions.

On the other hand, epidemiological exposure to pneumococci, as occurs when cohabiting with children, was associated with nasopharyngeal pneumococcal colonization in SOT recipients. A trend towards a higher incidence of pneumococcal nasopharyngeal carriage was also observed among non-vaccinated patients. An important issue to highlight is the low accomplishment of the recommendation of pneumococcal vaccination; only a fourth of patients had received it, which is significantly lower than that of other recommended vaccines such as influenza vaccination in the SOT population (40).

In one-fifth of the colonized patients, the serotype was non-tipable and a high serotype diversity, 21 serotypes, was observed, as reported in previous studies (36). Of the most prevalent serotypes found, serotypes 35B and 23A are not included in PPV23 and PCV13 vaccines, while serotype 19A is included in both vaccines. Serotype 35B has been reported as one of the most common serotypes in non-immunocompromised children and adults (41-44). In the present study, 54.4% of serotypes colonizing SOTR were not included in current vaccines (PPV23 and PCV13). The finding of non-vaccine serotypes colonizing SOTR is a fact to be assessed given that it represents the previous step to invasive disease in susceptible patients. Moreover, it allows us to study the potential invasiveness of the more unknown serotypes, which takes advantage of the ecological niche created by the disappearance of
vaccine able serotypes. Unfortunately, serotypes causing pneumococcal pneumonia could not be obtained in patients in this study and could, therefore, not be compared with those found in the nasopharynx of healthy SOTR. Despite this, the theoretical vaccine-preventable proportion of cases of IPD, using 13-valent vaccine in 2010 one year after its license in Europe, is estimated at 73% (45). The emergence of non-vaccine serotypes remains an important issue, and according to the European Centre for Disease Prevention and Control, continued monitoring in Europe is essential for assessing interventions and informing the development of new vaccines (1).

Few studies have analysed the serotypes of pneumococcus involved in SOTR pneumococcal diseases, most of them including patients with IPD. A study carried out in 2013 in Spain by Lujan et al. (3) concluded that the serotypes 10A, 11A, and 33F, not included in the PCV13 vaccine, were the most frequently isolated in immunocompromised patients with IPD although their prevalence was low (3). Kumar et al. (4) reported that the most frequent serotypes in SOT recipients with IPD were 23F, 22F, and 19F. They reported that only one-fourth of the SOT recipients with IPD had been previously vaccinated with PPV23 vaccine, and 65% and 85% of SOT recipients suffered an invasive pneumococcal disease caused by serotypes included in the PCV13 and PPV23 vaccines, respectively (4).

One-third of the isolates during the winter season were resistant to macrolides and cotrimoxazole, and 11% were resistant to quinolones. This proportion halved during the spring-summer season. Notably, the most prevalent serotype found (35B) presented 38% of resistance to macrolides and trimethoprim-sulfamethoxazole. Beall et al. (46), in 2002, also reported the high incidence of invasive serotype 35B in the US. In that study, 68 isolates (69%) were non-susceptible to penicillin; all of them with decreased susceptibility or non-susceptibility to cefotaxime and 11 isolates (16%) were resistant to trimethoprim-sulfamethoxazole. Moreover, in the present study, one penicillin-resistant isolate was highly resistant to cefotaxime (MIC, 8 µg/ml) and resistant to trimethoprim-sulfamethoxazole, tetracycline, erythromycin, clindamycin, and chloramphenicol. It is still not defined whether the resistance of certain serotypes to penicillin is due to innate biological features or the high usage of β-lactams antibiotics (46). A higher resistance of the serotype 35B has been reported recently from
isolates causing IPD in children, with 91% of the isolates penicillin non-susceptible, 46.2% erythromycin resistant, 21.8% trimethoprim-sulfamethoxazole resistant, and 16.7% were considered multidrug-resistant (42).

There were three cases of non-bacteraemia pneumococcal pneumonia during the study, only one of them previously colonized. However, two out of the three patients died, both with important comorbidities. None of these patients was previously vaccinated against pneumococcus. The absence of previous vaccination in SOTR had been linked to unfavourable IPD outcomes (46). Although the number of cases with non-bacteraemia pneumococcal pneumonia was too low in our study to establish robust conclusions, we consider that the unfavourable outcome strengthens the recommendation for pneumococcal vaccination in SOTR (47).

We should point out some limitations of this study. First, it is possible that some mild cases of pneumococcal disease were not diagnosed; however, no IPD cases were missed since all patients were carefully reviewed and guided to report any respiratory symptoms or fever during the study period. Secondly, the small number of cases of pneumococcal pneumonia did not permit to establish a robust association with the lack of pneumococcal vaccination. Finally, there was no official record of pneumococcal vaccination; consequently, this information is missing for 22.4% of the patients.

Conclusions
The present study shows that the rate of pneumococcal colonization in SOTR is low, similar to that reported in the general adult population. The incidence of non-bacteremic pneumococcal pneumonia was low, although two out of the three patients died, suggesting the need of pneumococcal vaccination for the SOTR.

List Of Abbreviations
SOTR: Solid organ transplant recipient; IPD: Invasive pneumococcal disease; MICs: Minimum inhibitory concentrations; CLSI: Clinical & Laboratory Standards Institute

Declarations
Ethics approval and consent to participate
The study was approved by the Ethical and Scientific Committees of the University Hospital Virgen del Rocío, Seville, Spain, and the Ministry of Health of la Junta de Andalucía, Spain (#PCV-IIG-2
(WI191483)). All patients provided written informed consent.

Consent for publication

Not applicable

Availability of data and material

The data used and/or analysed during the study are on the manuscript, any other data and/or analysis are available from the corresponding author.

Competing interests

The authors declare that they have no competing interests.

Funding

The present work has been supported by Pfizer, 2014 ASPIRE Awards in Vaccine Research in Europe (Pfizer Reference # WI191483), by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009) - co-financed by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014-2020. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions

CRO and TCC contributed equally to this work (joint first authors). CRO and TCC performed the experiments, analysed the results and wrote the manuscript. MGM and GLH helped performing the experiments. YS reviewed the manuscript. LMG and FGR included the patients in the study and reviewed the manuscript. JP helped with interpretation of the data, and revision of the manuscript. MPI designed and coordinated the experiments, and reviewed the results and the manuscript. EC obtained the funds to perform the studies and reviewed analysis and manuscript. All authors approved of the final draft.

Acknowledgements

The authors are grateful to the participants that collaborated in the study.

This work was presented in part at the 27th congress ECCMID is a European Congress of Clinical
Microbiology and Infectious Diseases

References

1. Annual epidemiological report 2016. European Centre for Disease Prevention and Control. 2016.
2. Prevention CfDCa. Active Bacterial Core surveillance (ABCs) . 2013 -present.
3. Lujan M, Burgos J, Gallego M, Falco V, Bermudo G, Planes A, et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(12):1722-30.
4. Kumar D, Humar A, Plevneshi A, Green K, Prasad GV, Siegal D, et al. Invasive pneumococcal disease in solid organ transplant recipients--10-year prospective population surveillance. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007;7(5):1209-14.
5. Cordero E, Pachon J, Rivero A, Giron JA, Gomez-Mateos J, Merino MD, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. American journal of respiratory and critical care medicine. 2000;162(6):2063-8.
6. Linnemann CC, Jr., First MR. Risk of pneumococcal infections in renal transplant patients. Jama. 1979;241(24):2619-21.
7. Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation. 1990;49(1):122-5.
8. de Bruyn G, Whelan TP, Mulligan MS, Raghu G, Limaye AP. Invasive pneumococcal
infections in adult lung transplant recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4(8):1366-71.

9. Yu VL, Chiou CC, Feldman C, Ortvqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2003;37(2):230-7.

10. Song JY, Nahm MH, Moseley MA. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. Journal of Korean medical science. 2013;28(1):4-15.

11. III SdIMCNdEIdSC. INFORME ANUAL DEL SISTEMA DE INFORMACIÓN MICROBIOLÓGICA 2012. 2014.

12. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;30(1):100-21.

13. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 1997;46(RR-8):1-24.

14. (CDC). CfDCaP. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Mmwr Morb Mortal Wkly Rep. 2012;61(40):816-9.

15. Danziger-Isakov L, Kumar D, Practice ASTIDCo. Vaccination in solid organ transplantation. American journal of transplantation: official journal of the American
15 Society of Transplantation and the American Society of Transplant Surgeons. 2013;13 Suppl 4:311-7.

16. Harris K, Baggs J, Davis RL, Black S, Jackson LA, Mullooly JP, et al. Influenza vaccination coverage among adult solid organ transplant recipients at three health maintenance organizations, 1995-2005. Vaccine. 2009;27(17):2335-41.

17. Diana A, Posfay-Barbe KM, Belli DC, Siegrist CA. Vaccine-induced immunity in children after orthotopic liver transplantation: a 12-yr review of the Swiss national reference center. Pediatric transplantation. 2007;11(1):31-7.

18. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PloS one. 2013;8(2):e56974.

19. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009;374(9700):1543-56.

20. Obando I, Sanchez-Tatay D, Molinos-Quintana A, Delgado-Pecellin I, Porras A, Morillo-Gutierrez B, et al. Epidemiology of nasopharyngeal carriage of Streptococcus pneumoniae in children < 6 years old in Seville. Enfermedades infecciosas y microbiologia clinica. 2011;29(8):581-6.

21. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004;38(5):632-9.

22. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. The Lancet Infectious diseases. 2004;4(3):144-54.

23. Glennie SJ, Banda D, Gould K, Hinds J, Kamngona A, Everett DD, et al. Defective pneumococcal-specific Th1 responses in HIV-infected adults precedes a loss of control of pneumococcal colonization. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America. 2013;56(2):291-9.

24. Nicoletti C, Brandileone MC, Guerra ML, Levin AS. Prevalence, serotypes, and risk factors for pneumococcal carriage among HIV-infected adults. Diagnostic microbiology and infectious disease. 2007;57(3):259-65.

25. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Sampling methods for the study of pneumococcal carriage: a systematic review. Vaccine. 2012;30(48):6738-44.

26. O'Brien KL, Nohynek H, World Health Organization Pneumococcal Vaccine Trials Carriage Working G. Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. The Pediatric infectious disease journal. 2003;22(2):e1-11.

27. Ing J, Mason EO, Kaplan SL, Lamberth LB, Revell PA, Luna RA, et al. Characterization of nontypeable and atypical Streptococcus pneumoniae pediatric isolates from 1994 to 2010. Journal of clinical microbiology. 2012;50(4):1326-30.

28. Ma X, Zhao R, Ma Z, Yao K, Yu S, Zheng Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive diseases from Shenzhen Children's Hospital. PloS one. 2013;8(6):e67507.

29. CLSI CaLSI-. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute 2018.

30. Iraurgui P, Torres MJ, Gandia A, Vazquez I, Cabrera EG, Obando I, et al. Modified sequential multiplex PCR for determining capsular serotypes of invasive pneumococci recovered from Seville. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2010;16(9):1504-7.

31. Gillis HD, Demczuk WHB, Griffith A, Martin I, Warhuus M, Lang ALS, et al. PCR-based discrimination of emerging Streptococcus pneumoniae serotypes 22F and 33F.
32. Shakrin NN, Balasubramaniam SD, Yusof HA, Mastuki MF, Masri SN, Taib NM, et al. Evaluation of PCR-based approach for serotype determination of Streptococcus pneumoniae. Tropical biomedicine. 2013;30(2):338-44.

33. Abdullahi O, Nyiro J, Lewa P, Slack M, Scott JA. The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. The Pediatric infectious disease journal. 2008;27(1):59-64.

34. Flamaing J, Peetermans WE, Vandeven J, Verhaegen J. Pneumococcal colonization in older persons in a nonoutbreak setting. Journal of the American Geriatrics Society. 2010;58(2):396-8.

35. Palmu AA, Kaijalainen T, Saukkoriipi A, Leinonen M, Kilpi TM. Nasopharyngeal carriage of Streptococcus pneumoniae and pneumococcal urine antigen test in healthy elderly subjects. Scandinavian journal of infectious diseases. 2012;44(6):433-8.

36. Almeida ST, Nunes S, Santos Paulo AC, Valadares I, Martins S, Breia F, et al. Low prevalence of pneumococcal carriage and high serotype and genotype diversity among adults over 60 years of age living in Portugal. PloS one. 2014;9(3):e90974.

37. Allemann A, Frey PM, Brugger SD, Hilty M. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland. Vaccine. 2017;35(15):1946-53.

38. Ousmane S, Diallo BA, Ouedraogo R, Sanda AA, Soussou AM, Collard JM. Serotype Distribution and Antimicrobial Sensitivity Profile of Streptococcus pneumoniae Carried in Healthy Toddlers before PCV13 Introduction in Niamey, Niger. PloS one. 2017;12(1):e0169547.
39. Numminen E, Chewapreecha C, Turner C, Goldblatt D, Nosten F, Bentley SD, et al. Climate induces seasonality in pneumococcal transmission. Scientific reports. 2015;5:11344.

40. Cordero E, Roca-Oporto C, Bulnes-Ramos A, Aydillo T, Gavalda J, Moreno A, et al. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;64(7):829-38.

41. Miyazaki H, Shibuya R, Midorikawa N, Chang B, Ohnishi M, Matsumoto T. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2017;23(4):234-40.

42. Olarte L, Kaplan SL, Barson WJ, Romero JR, Lin PL, Tan TQ, et al. Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States. Journal of clinical microbiology. 2017;55(3):724-34.

43. Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D, Jr., et al. Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. Antimicrobial agents and chemotherapy. 2015;59(9):5595-601.

44. Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shouji M, et al. Serotype Changes and Drug Resistance in Invasive Pneumococcal Diseases in Adults after Vaccinations in Children, Japan, 2010-2013. Emerging infectious diseases. 2015;21(11):1956-65.

45. (ECDC) ECfDPaC. Surveillance of invasive pneumococcal disease in Europe, 2010.
46. Beall B, McEllistrem MC, Gertz RE, Jr., Boxrud DJ, Besser JM, Harrison LH, et al. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. The Journal of infectious diseases. 2002;186(1):118-22.

47. van Veen KE, Brouwer MC, van der Ende A, van de Beek D. Bacterial meningitis in solid organ transplant recipients: a population-based prospective study. Transplant infectious disease : an official journal of the Transplantation Society. 2016;18(5):674-80.

Tables
Table 1. Baseline characteristics and outcome of patients according to their pneumococcus colonization status.
|                                    | Total \( n = 500 \) | Not colonized \( n = 461 \) | Colonized \( n = 39 \) | \( P \) OR (CI95%) |
|------------------------------------|----------------------|-----------------------------|------------------------|-------------------|
| **Sex (male) - n (%)**             | 322 (64.4)           | 291 (63.1)                  | 31 (79.5)              | <0.05 (0.20 - 0.98) |
| **Age years, median (range)**      | 54.4 (45-64)         | 54.5 (45-64)                | 53.8 (42-64)           | ns                |
| **Type of transplant- n (%)**      |                      |                             |                        |                   |
| · Kidney                           | 353 (70.6)           | 324 (70.3)                  | 29 (74.4)              | ns                |
| · Liver                            | 106 (21.2)           | 100 (21.7)                  | 6 (15.4)               |                   |
| · Heart                            | 39 (7.8)             | 35 (7.6)                    | 4 (10.3)               |                   |
| · Liver-kidney                     | 2 (0.4)              | 2 (0.4)                     | 0 (0)                  |                   |
| **Time from transplant, median (range)** |                  |                             |                        |                   |
| · 0-180 days                       | 94 (18.8)            | 88 (19.1)                   | 6 (15.4)               | ns                |
| · >180-360 days                    | 34 (6.8)             | 31 (6.7)                    | 3 (7.7)                |                   |
| · >1-5 years                       | 139 (27.8)           | 131 (28.4)                  | 8 (20.5)               |                   |
| · > 5 years                        | 233 (46.6)           | 211 (45.8)                  | 22 (56.4)              |                   |
| **Charlson Comorbidity Index**     |                      |                             |                        |                   |
| · 0 point                          | 110 (22)             | 103 (22.3)                  | 7 (17.9)               | ns                |
| · 1 points                         | 94 (18.8)            | 89 (19.3)                   | 5 (12.8)               |                   |
| · ≥3 puntos                        | 83 (16.6)            | 76 (16.5)                   | 7 (17.9)               |                   |
|                                    | 213 (42.6)           | 193 (41.9)                  | 20 (51.3)              |                   |
| **Cohabiting children- n (%)**     | 172 (34.4)           | 149 (32.3)                  | 23 (59)                | 0.001 (1.55 - 5.87) |
| · Children pneumococcal vaccination| 18 (3.6)             | 17 (4.3)                    | 1 (2.8)                | ns                |
| **Prior pneumococcal infection- n (%)** | 44 (8.8)             | 38 (8.2)                    | 6 (15.4)               | ns                |
| **Prior pneumococcal vaccine- n (%)** | 121 (24.2)           | 115 (24.9)                  | 6 (15.4)               | ns                |
| **Baseline immunosuppression- n (%)** |                      |                             |                        |                   |
| · Tacrolimus                       | 409 (81.8)           | 375 (81.3)                  | 34 (87.2)              |                   |
| · Mycophenolate                    | 377 (75.4)           | 347 (75.3)                  | 30 (76.9)              |                   |
| · Ciclosporine                     | 58 (11.6)            | 55 (11.9)                   | 3 (7.7)                |                   |
| · mTOR                             | 79 (15.8)            | 75 (16.3)                   | 4 (10.3)               |                   |
| · Azathioprine                     | 10 (2)               | 10 (2.2)                    | 0 (0)                  |                   |
| · Glucocorticoids                  | 326 (65.2)           | 304 (65.9)                  | 22 (56.4)              |                   |
| **Thymoglobulin induction <6 m- n (%)** | 28 (5.6)             | 26 (5.6)                    | 2 (5.1)                | ns                |
| **Prior organ rejection**          | 77 (15.4)            | 70 (15.2)                   | 7 (17.9)               | ns                |
| **Outcomes: - n (%)**              |                      |                             |                        |                   |
| · Pneumococcal infection           |                      |                             |                        |                   |
| · Death                            | 3                    | 2 (0.4)                     | 1 (2.5)                | ns                |
| · Rejection                        | 9                    | 9 (2)                       | 0 (0)                  |                   |
| · Graft loss                       | 2                    | 2 (0.4)                     | 0 (0)                  |                   |
|                                    | 7                    | 7 (1.6)                     | 0 (0)                  |                   |

Abbreviations: OR: odds ratio. CI: Confidence Interval. mTOR: mammalian Target of Rapamycin. ns = not significant.

Table 2. Non-bacteraemic pneumococcal pneumonia cases in SOT recipients.
### Table 3. Multivariable analysis: factors potentially related to pneumococcal nasopharyngeal carriage in solid organ transplant recipients.

| Variable                                      | OR (CI95%)          | p    |
|-----------------------------------------------|---------------------|------|
| Sex (male vs. female)                        | 0.44 (0.20 - 0.98)  | 0.046|
| Cohabiting children (yes vs. no)             | 2.95 (1.50 - 5.77)  | 0.002|
| Prior pneumococcal vaccination (yes vs. no)  | 0.59 (0.24 - 1.45)  | 0.247|

Abbreviations: OR: odds ratio. CI: Confidence Interval
Table 4. *In vitro* activities of 11 antibiotics against *S. pneumoniae* clinical isolates from SOT recipients.

| Antibiotic               | CLSI breakpoints\(^a\) (of isolates) | PK/PD Breakpoint (µg/ml) |
|--------------------------|---------------------------------------|--------------------------|
|                          | Susceptible | Intermediate | Resistant | Susceptibility (of isolates) | |
| O. Penicillin            | 39.39       | 51.52        | 9.09      | 39.39                       | ≤0.06 |
| I. Penicillin            | 100         | 0            | 0         | 100                         | ≤2    |
| Amoxicillin              | 87.88       | 9.09         | 3.03      | 87.88                       | ≤2    |
| Cefotaxime               | 100         | 0            | 0         | 100                         | ≤1    |
| Ceftriaxone              | 96.97       | 3.03         | 0         | 96.97                       | ≤1    |
| Azithromycin             | 53.03       | 16.67        | 30.30     | 53.03                       | ≤0.5  |
| Erythromycin             | 66.67       | 3.03         | 30.30     | 66.67                       | ≤0.25 |
| Clarithromycin           | 71.21       | 0            | 28.79     | 71.21                       | ≤0.25 |
| Levofoxacin              | 75.76       | 24.24        | 0         | 75.76                       | ≤2    |
| Vancomycin               | 100         | 0            | 0         | 100                         | ≤1    |
| Trimethoprim-sulfamethoxazole | 53.03     | 16.67        | 30.30     | 53.03                       | ≤0.5  |

**Abbreviations:** O.: oral; I.: intravenous

\(^a\)The CLSI breakpoints used were ≤0.06 mg/L (susceptible), 0.12 to 1 mg/L (intermediate), and ≥2 mg/L (resistant) for oral penicillin and ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥8 mg/L (resistant) for intravenous penicillin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥8 mg/L (resistant) for amoxicillin; ≤1 mg/L (susceptible), 2 mg/L (intermediate), and ≥4 mg/L (resistant) for cefotaxime and ceftriaxone; ≤0.5 mg/L (susceptible), 1 mg/L (intermediate), and ≥2 mg/L (resistant) for azithromycin; ≤0.25 mg/L (susceptible), 0.5 mg/L (intermediate), and ≥1 mg/L (resistant) for erythromycin and clarithromycin; ≤2 mg/L (susceptible), 4 mg/L (intermediate), and ≥8 mg/L (resistant) for levofloxacin; ≤1 mg/L (susceptible) for vancomycin; and ≤0.5 mg/L (susceptible), 1-2 mg/L (intermediate), and ≥4 mg/L (resistant) for trimethoprim-sulfamethoxazole.

**Figures**
Figure 1
Serotypes seasonal distribution of the identified pneumococcal isolates. NS: No capsular serotypes

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary material 23.04.19.docx
Table 1.jpg